Vortioxetine in Depression and Concomitant Migraine (VORTIX)
Vortioxetine in the Treatment of Depression and Concomitant Migraine: an Explorative Study
Depression and migraine are among the most prevalent conditions in the general population, and many research shows they are closely related. Migraine is one of the most common debilitating diseases, affecting over one billion people worldwide. Migraine is frequently comorbid with psychiatric conditions such as anxiety disorders and major depression, with a negative impact on quality of life (QoL) and disability.
The knowledge of the pathophysiology of migraine involves changes in physiological processes, functional connectivity, and structural changes of the central nervous system (CNS) in patients with underlying genetic susceptibility. Upregulation of vasoactive and pro-inflammatory mediators such as calcitonin gene-related peptide (CGRP) and cytokines have been found in the trigeminal ganglia and the plasma, cerebrospinal fluid, saliva, and tears of these patients.
Various classes of antidepressants - like Selective Serotonin Reuptake Inhibitors (SSRI), Selective Serotonin and Norepinephrine Inhibitors (SNRI), and Tricyclic Antidepressants (TCAs) - were investigated but in a low number of studies and with inconsistent results.
Vortioxetine (VO) is a novel multimodal serotonergic antidepressant, approved in the last decade for the treatment of major depression. VO inhibits 5-HT transporter (SERT), like commonly used antidepressants, but different from them, it directly modulates the activity of 5-HT receptors. Vortioxetine also modifies the release of glutamate and gamma amino butyric acid (GABA), implicated in migraine pathogenesis. Recent experimental and clinical studies have shown that VO exerts antidepressant and pro-cognitive activities and is also effective in modulating pain hypersensitivity and could be effective in treating chronic pain syndromes.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Catello Vollono, MD
- 전화번호: +390630154279
- 이메일: catello.vollono@policlinicogemelli.it
연구 장소
-
-
Lazio
-
Rome, Lazio, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurofisiopatologia
-
연락하다:
- Catello Vollono, MD
- 전화번호: +390630154279
- 이메일: catello.vollono@policlinicogemelli.it
-
수석 연구원:
- Catello Vollono, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- The patient is aged >18 years old
- The patient has a diagnosis of depression, according to DSM-5, and in treatment with Vortioxetine (for no more than a week).
- Patients with depression and anxiety symptoms will also be included in the study
- The patient had a score of the HAM-D >18 (moderate to severe)
- The patient has a diagnosis of episodic migraine with and without aura according to ICHD-3 criteria confirmed at the Screening Visit with a history of migraine onset of at least one year before the Screening Visit
- No concomitant other treatment for depression
- The patient has had an onset of migraine at <50 years of age
- All participating patients will provide written informed consent
- No concomitant preventive treatment for migraine with TCAs, other antidepressants, anti-CGRP monoclonal antibodies (mAbs) or gepants. The patient is not eligible for treatment with anti-CGRP mAbs
- Stable treatment for migraine for at least two months without prevision to change it in the next two12 weeks
Exclusion Criteria:
- The patient has confounding and clinically significant pain syndromes (for example, chronic low back pain and fibromyalgia)
- The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), or migraine with brainstem aura
- Patients with a lifetime history of psychosis, bipolar mania
- Patients with cognitive impairment are excluded (MoCA <26)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response to Vortioxetine
기간: 6 months
|
To evaluate the modification of depression after 12 weeks of treatment with Vortioxetine (VO) through clinical examination and questionnaire administration
|
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change of depressive and anxiety symptoms
기간: 6 months
|
To evaluate the response to VO in term of change of depressive and anxiety symptoms through clinical examination and questionnaire administration
|
6 months
|
|
Change of migraine outcomes
기간: 6 months
|
To evaluate the response to VO in term of change of migraine outcomes through clinical examination and questionnaire administration
|
6 months
|
|
Change of a specific biomarkers
기간: 6 months
|
To evaluate the response to VO in term of change of a specific biomarkers by measuring endocannabinoid levels before and after treatment
|
6 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Catello Vollono, MD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .